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Angiogenesis is a critical component of the inflamma-
tory response associated with a number of conditions.
Angiopoietin-1 (Ang-1) is an angiogenic growth factor
that promotes the chemotaxis of endothelial cells and
facilitates the maturation of new blood vessels. Ang-1
expression is up-regulated in response to tumor necro-
sis factor- (TNF-). To begin to elucidate the underly-
ing molecular mechanisms by which Ang-1 gene expres-
sion is regulated during inflammation, we isolated 3.2
kb of the Ang-1 promoter that contain regulatory ele-
ments sufficient to mediate induction of the promoter in
response to TNF-, interleukin-1, and endotoxin. Sur-
prisingly, sequence analysis of this promoter failed to
reveal binding sites for transcription factors that are
frequently associated with mediating inflammatory
responses, such as NF-B, STAT, NFAT, or C/EBP. How-
ever, putative binding sites for ETS and AP-1 transcrip-
tion factor family members were identified. Interest-
ingly, among a panel of ETS factors tested in a transient
transfection assay, only the ETS factor ESE-1 was capa-
ble of transactivating the Ang-1 promoter. ESE-1 binds
to specific ETS sites within the Ang-1 promoter that are
functionally important for transactivation by ESE-1.
ESE-1 and Ang-1 are induced in synovial fibroblasts in
response to inflammatory cytokines, with ESE-1 induc-
tion slightly preceding that of Ang-1. Mutation of a high-
affinity ESE-1 binding site leads to a marked reduction
in Ang-1 transactivation by ESE-1, inducibility by in-
flammatory cytokines, and DNA binding to the ESE-1
protein. Transcriptional profiling of cells transiently
transfected with an ESE-1 expression vector demon-
strates that the endogenous Ang-1 gene is directly in-
ducible by ESE-1. Finally, Ang-1 and ESE-1 exhibit a
similar and strong expression pattern in the synovium
of patients with rheumatoid arthritis. Our results sup-
port a novel paradigm for the ETS factor ESE-1 as a
transcriptional mediator of angiogenesis in the setting
of inflammation.
Inflammation is an important component of several patho-
logical conditions, including wound healing, atherosclerosis,
and arthritis. Inflammation is often associated with the devel-
opment of granulation tissue consisting of infiltrating mononu-
clear cells and blood vessels (1, 2). As this tissue proliferates
there are zones of relative hypoxia where growth of the tissue
has outstripped the blood vessel supply, triggering signals for
further blood vessel development (3). The angiogenesis that
results from these signals provides the necessary blood supply,
oxygen, and nutrients to support the proliferating tissue, and
plays an active role in the transport of inflammatory cells to the
site of inflammation (4). The endothelial cells themselves also
provide a source of proinflammatory cytokines.
One of the first steps in this process is the induction of
angiogenic growth factors such as basic fibroblast growth factor
(bFGF)1 and vascular endothelial growth factor (VEGF) (5).
These growth factors promote the proliferation and migration
of endothelial cells to sites of inflammation, which is facilitated
by the expression of matrix degrading enzymes and integrins
on activated endothelial cells (6). Endothelial cells that have
migrated to sites of inflammation then organize into small
tubes. The formation of stable blood vessels requires the re-
cruitment of surrounding mesenchymal cells and their differ-
entiation into vascular smooth muscle cells. Vessel maturation
is facilitated by the angiopoietins (7).
Ang-1 has the unique property of enhancing the stability of
new blood vessels by recruiting surrounding mesenchymal cells
and promoting their differentiation to vascular smooth muscle
cells (7). In contrast to other angiogenic substances like VEGF
or bFGF, Ang-1 is not a potent mitogen for endothelial growth.
However, Ang-1 is a potent chemoattractant of endothelial cells
and enhances endothelial cell migration. Other properties of
Ang-1 include its ability to promote the adhesion of endothelial
cells to fibronectin, as well as its ability to prevent endothelial
cell death by inhibiting apoptosis (8, 9).
We and others (10–12) have recently demonstrated that
Ang-1 mRNA and protein are expressed in the synovium of
patients with rheumatoid arthritis (RA). Ang-1 is expressed at
low levels in primary human synovial fibroblasts obtained from
patients with RA, and can be markedly up-regulated in re-
sponse to inflammatory cytokines such as TNF-. However, the
transcriptional mechanisms by which Ang-1 gene expression is
regulated are currently unknown.
The purpose of this study was to begin to identify the molec-
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inflammation. Our findings support a central role for the ETS
transcription factor ESE-1 during this process. ESE-1 was orig-
inally identified as a transcription factor that, under basal
conditions, is highly restricted to cells of epithelial origin (13).
However, in response to inflammatory stimuli, this factor can
be induced in a variety of non-epithelial cells, including vascu-
lar smooth muscle cells, chondrocytes, synovial fibroblasts, and
endothelial cells (14, 15). We recently demonstrated that ESE-1
is highly expressed in the synovium of patients with rheuma-
toid arthritis (15). In this study we present direct evidence
indicating a role for ESE-1 in Ang-1 gene regulation. ESE-1 can
bind to specific ETS sites within the Ang-1 promoter that are
functionally important for the transactivation by ESE-1, ex-
pression of ESE-1 in cultured cells leads to induction of the
endogenous Ang-1 gene, and Ang-1 exhibits a similar and
strong expression pattern in the synovium of patients with RA.
In summary, our results support a role for the ETS factor
ESE-1 as a novel transcriptional regulator of Ang-1 gene reg-
ulation in the setting of inflammation.
EXPERIMENTAL PROCEDURES
Tissue Culture and Reagents—The cell lines HEK293 (human em-
bryonic kidney), NIH3T3 (mouse fibroblast), and MCF-7 (human breast
cancer) were grown in DMEM supplemented with 10% fetal calf serum
(FCS; Hyclone, Logan, UT) and antibiotics (penicillin and streptomycin;
Invitrogen). Synovial tissue and bone were obtained at the time of
arthroplasty or joint replacement surgery from patients with the clin-
ical diagnosis of RA. Tissue procurement was approved by the Institu-
tional Review Board. Dispersed synovial tissues were prepared by a
previously published method (16). Briefly, synovial tissues were minced
on tissue culture plates and treated with Type I collagenase (4 mg/ml;
Worthington Biochemical Corporation, Lakewood, NJ), in DMEM (In-
vitrogen), incubated for 1 h at 37 °C, treated with 0.25% trypsin for 30
min, harvested, and centrifuged at 1,000 rpm for 10 min. Pellets were
suspended in 0.05% trypsin-0.02% EDTA, centrifuged, and resus-
pended in 50% phosphate-buffered saline (Ca2/Mg2-free), 50%
DMEM containing 10% FCS (Sigma). Cells were then centrifuged and
suspended in DMEM, 10% FCS, and plated at a density of 10  106
cells/10-cm plate. Cells were initially grown for 7–10 days and subse-
quently subjected to 2–4 passages. TNF- and interleukin-1 (IL-1)
were purchased from R&D Systems (Minneapolis, MN).
Expression Vector and Luciferase Reporter Gene Constructs—3239-,
1998-, and 1020-bp fragments corresponding to nucleotides 3040 to
199, 1799 to 199, and 821 to 199 of the human Ang-1 promoter
were cloned from human genomic DNA (Clontech, Palo Alto, CA) by
PCR and subcloned into the pGL2 luciferase reporter vector (Promega,
Madison, WI). The 1998- and 1020-bp fragments were inserted into the
XhoI-HindIII site and the 3239-bp fragment was inserted into the
HindIII site upstream of the luciferase gene of the pGL2 vector.
DNA Transfection Assays—Cotransfections of 2  105 HEK293 or
NIH3T3 cells were carried out with varying amounts of reporter gene
construct DNA and expression vector DNA using 4 l of Lipo-
fectAMINE (Invitrogen) as described (17). The cells were harvested 16 h
after transfection and assayed for luciferase activity. Transfections for
every construct were performed independently in duplicates. Cotrans-
fection of a second plasmid for determination of transfection efficiency
was omitted because potential artifacts with this technique have been
reported and because many commonly used viral promoters contain
potential binding sites for ETS factors (18).
Site-directed Mutagenesis—Site-directed mutagenesis of the Ang-1
promoter was performed using the QuikChange site-directed mutagen-
esis kit (Stratagene) according to the manufacturer’s recommendations.
In brief, PCR primers encoding the Ang-1 promoter ETS site, 1565 to
1562, and flanking sequences were used, with ATAT substituted for
ATCC: 5-TGTGAATTACATATTGTTAGCCTT-3 and 3-AAGGCTAA-
CAATATGTAATTCACA-5. PCR was performed with Turbo polymer-
ase using the wild type Ang-1 promoter fragment C luciferase reporter
construct as a template. The PCR reaction was digested with DpnI, and
the undigested plasmids were transformed into DH5 bacteria. Indi-
vidual minipreps were sequenced to verify incorporation of the ETS site
mutation.
Electrophoretic Mobility Shift Assay—These were performed as de-
scribed previously (19). In brief, whole cell extracts were made from
primary human synovial fibroblasts after incubation with TNF- or
IL-1 for 0, 2, 6, 18, 24, and 48 h, using as lysis buffer 10% glycerol,
0.5% Nonidet P-40, 150 mM NaCl, 10 mM Tris pH 7.4, 1 mM phenyl-
methanesulfonyl fluoride, and 1 mM dithiothreitol. Whole cell extracts
were obtained instead of nuclear extracts because the number of cells
were limited and the primary synovial fibroblasts do not maintain their
phenotype after 4–5 passages. 10 g of whole cell extract or 2 l of in
vitro translation product and 0.1–0.2 ng of [32P]dATP-labeled double-
stranded oligonucleotide probes (5,000–20,000 cpm) in the presence or
absence of antibody were run on 4% polyacrylamide gels containing
0.5 TBE buffer. For supershift assays, 1 l of rabbit polyclonal anti-
ESE-1 antibody raised against a glutathione S-transferase fusion pro-
tein of the N terminus of human ESE-1 (East Acres Biologicals, South-
bridge, MA) was used.
Oligonucleotides used as probes are as follows (ETS consensus bind-
ing sites underlined: 1) human Ang-1 promoter site 2586 to 2567,
5-TTTAATGCATCCTGAATTCT-3 and 3-AGAATTCAGGATGCATT-
AAA-5; 2) human Ang-1 promoter site 2207 to 2188, 5-TTCCCT-
CAGGAAATTGTGCA-3 and 3-TGCACAATTTCCTGAGGGAA-5; 3)
human Ang-1 promoter site 1573 to 1554, 5-TGAATTACATCCTG-
TTAGCC-3 and 3-GGCTAACAGGATGTAATTCA-5; 4) human Ang-1
promoter mutated site 1573 to 1554, 5-GCTCTGTTGAATTACAT-
ATTGTTAGCCTTTC-3 and 3-GAAAGGCTAACAATATGTAA-
TTCACAGAGC-5.
RT-PCR—Total RNA was isolated using the RNeasy Mini Kit (Qia-
gen, Valencia, CA). cDNAs were generated from 2 g of mRNA isolated
from human synovial fibroblasts using oligo(dT)12–18 priming (Invitro-
gen) and Moloney murine leukemia virus-reverse transcriptase (In-
vitrogen). ESE-1, AML-1, and GAPDH RT-PCRs used equivalent
amounts of 0.1 ng of cDNA, 4 ng/l of each primer, 0.25 units of Taq
polymerase (Promega), 150 M of each dNTP, 3 mM of MgCl2, reaction
buffer, and water to a final volume of 25 l. Ang-1 RT-PCRs used
equivalent amounts of 0.1 ng of cDNA, 4 ng/l of each primer, 0.25 units
of Advantage cDNA polymerase mix (Clontech), 150 M of each dNTP,
reaction buffer, and water to a final volume of 25 l.
The sequences of the primers used in this study are as follows: 1)
Human ESE-1: sense, 5-ACCTGGATCCCACTGATGGCAAGCTC-3
and antisense, 5-GGAGGAAGAGGTTCTCCAGAGTCGG-3, with an
expected amplification product of 457 bp. 2) Human Ang-1: sense,
5-TTTCCTCGCTGCCATTCTGACTC-3, and antisense, 5-TATGGAT-
GTCAATGGGGGAGGTT-3, with an expected amplification product of
947bp. 3) Human AML-1: sense, 5-AAGTCGCCACCTACCACAG-3
and antisense, 5-CTCAGCCTCAGAGTCAGATGC-3, with an expected
amplification product of 248 bp (21). 4) Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH): sense, 5-CAAAGTTGTCATGGATGACC-3
and antisense, 5-CCATGGAGAAGGCTGGGG-3, with an expected
amplification product of 200 bp.
RT-PCR amplifications were carried out using a MJ Research ther-
mal cycler PTC-100 as follows: ESE-1, 32 cycles of 30 s at 94 °C and 1
min 30 s at 68 °C followed by 7 min at 68 °C; Ang-1, 35 cycles of 30 s at
94 °C, and 1 min 30 s at 64 °C followed by 7 min at 64 °C; AML-1, 32
cycles of 30 s at 94 °C, 1 min at 60 °C, and 1 min 30 s at 72 °C followed
by 10 min at 72 °C; GAPDH, 32 cycles of 30 s at 94 °C, 1 min at 56 °C,
and 1 min 30 s at 72 °C followed by 10 min at 72 °C. 5 l of the
amplification product was analyzed on a 2% agarose gel.
Western Blot Analysis—Whole cell lysates (50 g) of MCF7 cells were
boiled in Laemmli buffer and resolved on 10% SDS-PAGE acrylamide
gel. Proteins were transferred on Hybond-polyvinylidene difluoride
membranes and immunoblotted using the ECL Western blotting Detec-
tion reagents (Amersham Biosciences). Rabbit polyclonal anti-ESE-1
antibody raised against a glutathione S-transferase fusion protein of
the N terminus of human ESE-1 (East Acres Biologicals, Southbridge,
MA) was used at a dilution of 1:1,000, and revealed with an anti-rabbit
horseradish peroxydase antibody (Cell Signaling Technology, Beverly,
MA) at a dilution of 1:1,000.
cDNA Microarrays—Microarray experiments were performed as pre-
viously described (22). In brief, 1  106 human breast cancer MCF-7
cells were transiently transfected in duplicates with 8 g of PCI-ESE-1
or PCI plasmid using the LipofectAMINE Plus system (Invitrogen).
Total RNA was isolated separately from each plate 24 h after transfec-
tion using the RNeasy Kit (Qiagen) according to the manufacturer’s
instructions. Atlas Human Cancer 1.2 cDNA microarray nylon mem-
branes (Clontech), each containing 1176 different genes, were hybrid-
ized with [32P]dATP-labeled cDNAs derived from 4 g of total RNA
according to the manufacturer at 68 °C in ExpressHyb solution (Clon-
tech) using a Model 2000 Micro Hybridization Incubator (Robbins Sci-
entific, Sunnyvale, CA). The filters were washed according to the user’s
instruction and exposed to Bio-Max MS film (Fisher) for different ex-
posure times. Hybridizations were performed with duplicate experi-
ments. The spot intensities reflecting gene expression levels on the
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Atlas human cDNA array were quantified using the Atlas Image 2.0
Software (Clontech). The transcriptional profiles in the cells overex-
pressing ESE-1 were compared with those in the cells transfected with
parental PCI vector, normalizing spot intensities based on the average
of the intensities of all spots. Genes up-regulated or down-regulated by
ESE-1 were validated by RT-PCR.
Immunohistochemistry—RA synovial soft tissue and bone were fixed
for 48 h in 4% paraformaldehyde and specimens containing bone were
subsequently decalcified for at least 2 weeks in 14% EDTA. Specimens
were processed for paraffin embedding (Citadel 1000; Shandon, Pitts-
burgh, PA) and 4- or 5-m serial sections were cut for immunohisto-
chemical staining using an immunoperoxidase technique with diami-
nobenzidine (DAB; Dako, Carpinteria, CA) as the chromogen. Briefly,
sections were deparaffinized followed by microwave antigen retrieval
(GE Sensor convection microwave oven) in 10 mM EDTA pH 7.5 at 93 °C
for 10 min and allowed to cool for at least 2 h. Sections were washed in
Tris-buffered saline (TBS) and incubated for 60 min in serum block
(10% fetal bovine serum and 10% normal rabbit serum diluted in TBS).
Sections were then incubated with an affinity purified rabbit polyclonal
anti-human Ang-1 antibody (L41309M, Regeneron Pharmaceuticals
Inc., Tarrytown, NY), purified rabbit polyclonal anti-human ESE-1
antibody (AB3482, Chemicon International, Temecula, CA), or with an
isotype matched control antibody (polyclonal Rabbit IgG, Santa Cruz
Biotechnology Inc, Santa Cruz, CA) for 60 min. All incubations were
carried out at room temperature. Sections were washed between every
subsequent step with TBS. Endogenous peroxidase activity was blocked
by incubating the sections in 3% H2O2 (diluted in TBS) for 30 min.
Sections were subsequently incubated for 30 min with a biotinylated
F(ab)2 fragment of swine anti-rabbit immunoglobulin (Dako), followed
by horseradish peroxidase-conjugated streptavidin (Dako), and devel-
oped with DAB (Dako) chromogen to the manufacturer’s specifications.
The sections were counterstained with hematoxylin (Sigma Diagnos-
tics). Slides were examined and photographed using a transmitted light
microscope and camera (Zeiss, Oberkochen, Germany).
RESULTS
Isolation and Characterization of the Human Ang-1 Promoter—
The molecular mechanisms required for the induction of Ang-1 in
response to inflammatory cytokines are currently unknown. To
begin to identify potential mechanisms of Ang-1 gene regulation we
isolated a series of genomic fragments (Fig. 1, A–C) of the human
Ang-1 promoter, up to 3.2 kb in length, by long range PCR using
human genomic DNA. The entire sequence of the Ang-1 gene is
published in the human genome data base (accession NT 008046).
Verification of the sequence was performed by automated sequenc-
ing. Comparison of the mouse and human Ang-1 promoter se-
quences revealed a relatively high overall degree of sequence ho-
mology. We examined the human Ang-1 promoter sequence for
potential binding sites for transcription factors known to be in-
volved in inflammation, such as NF-B, JAK/STAT, PPAR, NFAT,
and C/EBP. Surprisingly, no obvious binding site for any of these
transcription factor families was identified. However, putative
binding sites for members of the AP-1 and ETS families were
identified. In addition, putative AML-1 and CBF- binding sites
were identified in the Ang-1 promoter.
Induction of the Ang-1 Promoter by Inflammatory Cyto-
kines—To evaluate whether the Ang-1 promoter contains reg-
ulatory elements capable of mediating induction in response to
inflammatory cytokines the three genomic fragments encoding
the Ang-1 promoter (A–C) were incorporated into the pGL2
luciferase reporter construct. NIH3T3 fibroblasts were tran-
siently transfected with each Ang-1 reporter construct, fol-
lowed by stimulation with TNF- (Fig. 2A). We have previously
demonstrated that TNF- consistently induces Ang-1 mRNA
expression in cultured synovial fibroblasts (10). Stimulation of
the 3.2-kb Ang-1 promoter construct C (3040/199) with
TNF- resulted in a 4-fold induction of the promoter. Similarly,
stimulation of the 2-kb construct B (1799/199) with TNF-
led to a 4-fold increase in transactivation. However, further
deletion to a 1-kb construct (Ang-1 A, 821/199) markedly
reduced the inducibility of the promoter to TNF-, suggesting
that the main regulatory elements responsible for mediating
FIG. 1. Schematic of the human Ang-1 promoter. Ang-1 promoter, first exon, and intron, spanning from 3040 to 1823. Putative ETS
(filled circles) and AP-1 (filled triangles) binding sites are shown, as well as AML-1 (filled squares) and CBF- (filled diamonds) binding sites.
Deletion constructs of the proximal promoter (A–C) and sequence homology between the human and mouse sequences are also depicted.
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induction of the Ang-1 gene reside in the nucleotide region
between1799 and821. We also examined the inducibility of
constructs A and B in NIH3T3 fibroblasts after stimulation
with IL-1 and LPS (Fig. 2, B and C). A 4–5-fold level of
induction of the activity of construct B was seen in response to
IL-1 and LPS, but no induction was seen with construct A,
suggesting the importance of regulatory elements between nu-
cleotides 1799 and 821 in mediating this induction of Ang-1
gene expression. This region contains putative AP-1 and ETS
binding sites (Fig. 1).
Transactivation of the Ang-1 Promoter by ETS Factors—As
shown in Fig. 1, there are several putative binding sites for
members of the ETS transcription factor family in the Ang-1
promoter. Selected members of the ETS transcription factor
family have been shown previously to mediate the induction
of other genes associated with inflammatory responses (23,
24). We therefore postulated that ETS factors might also be
involved in the regulation of Ang-1 in response to inflamma-
tory stimuli and tested the ability of a panel of ETS factors to
transactivate the full-length Ang-1 promoter. Cotransfection
experiments using mammalian expression plasmids encoding
a panel of ETS factors and the 3.2-kb Ang-1 promoter lucif-
erase construct were performed in HEK293 cells. We chose
HEK293 cells because they do not express Ang-1 and can be
transfected with high efficiency. As is shown in Fig. 3, only
one of the ETS factors tested, ESE-1, was able to transacti-
vate the Ang-1 promoter by 3-fold. These results suggest
that ESE-1 is a potential transcriptional regulator of the
Ang-1 promoter.
Binding of ESE-1 to Putative ETS Binding Sites—To further
define the potential role of ESE-1 in the regulation of Ang-1, we
evaluated the ability of ESE-1 to bind to putative ETS binding
sites identified in the Ang-1 promoter by performing gel mobil-
ity shift assays. Three putative ETS binding sites were identi-
fied in the Ang-1 promoter corresponding to regions beginning
at 2578, 2199, and 1565 (Fig. 1). The binding of in vitro
translated ESE-1 protein was compared with control extracts
in a gel mobility shift assay using radiolabeled oligonucleotides
encoding the three putative ETS binding sites (Fig. 4). Whereas
weak binding of ESE-1 to the first two sites (lanes 2 and 4)
compared with the control extract (lanes 1 and 3) was observed,
ESE-1 bound with high affinity to the third site (lane 6). Inter-
estingly, this high affinity ESE-1 binding site (1565/1562) is
located within the region of the Ang-1 promoter that is required
for induction by inflammatory cytokines, whereas the low af-
finity sites are not.
Mutational Analysis of the Ang-1 Promoter ETS Binding
Site—To assess the functional importance of the high affinity
ESE-1 binding site, we mutated the ETS site corresponding to
the region beginning at 1565 within the Ang-1 luciferase
reporter construct C and evaluated the ability of ESE-1 to
transactivate the mutant construct compared with the wild
type Ang-1 promoter construct C (Fig. 5). Whereas ESE-1 was
able to increase transactivation of the wild type Ang-1 pro-
FIG. 2. Transactivation of the Ang-1 promoter in response to inflammatory stimuli. Transactivation studies of Ang-1 luciferase reporter
constructs A (821/199), B (1799/199), and C (3040/199) (300 ng each) in NIH3T3 fibroblasts after stimulation with TNF- (50 ng/ml) (A),
IL-1 (1 ng/ml) (B), or LPS (1 ng/ml) (C). The change in luciferase activity of the promoter construct after stimulation is expressed as fold induction
compared with the activity of the promoter construct in unstimulated cells (DMEM supplemented with 10% FCS).
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moter more than 8-fold and in a dose-dependent manner, only
a minimal increase in transactivation of the mutated Ang-1
promoter was observed, even at the highest doses of ESE-1.
The effect of the ETS mutation on the inducibility of the pro-
moter in response to inflammatory cytokines was also tested
(Fig. 5B). This mutation led to a marked reduction in the
inducibility of the promoter in response to the inflammatory
cytokine TNF-. We also tested the ability of ESE-1 to bind to
a mutated ETS binding site through gel mobility shift assay
analysis. As shown in Fig. 5C, the binding of in vitro translated
ESE-1 protein compared with control extract was blocked by
the mutated high-affinity ESE-1 binding site (1565/1562).
An antibody to ESE-1 also blocked the binding of in vitro ESE-1
protein to the wild type high affinity ESE-1 binding site
(1565/1562) compared with control extract, specifying that
the protein binding to the high affinity site is indeed ESE-1.
These results, together with Fig. 4, provide further support
that the ETS binding site corresponding to the region begin-
ning at 1565 is required for the transactivation of the Ang-1
promoter by ESE-1.
Expression of ESE-1 and Ang-1 in Response to Inflammatory
Cytokines—Having demonstrated the potential role for the
ETS factor ESE-1 as a transcriptional regulator of the Ang-1
promoter, we wished to examine the temporal relationship
between Ang-1 and ESE-1 expression in primary cells after
stimulation with inflammatory cytokines. Primary human sy-
novial fibroblasts have been shown to express low levels of
Ang-1 at base line (10). The levels of Ang-1 expression can be
markedly increased in response to TNF-. We therefore eval-
uated the temporal expression of ESE-1 and Ang-1 in primary
synovial fibroblasts after stimulation with IL-1 and TNF-.
As is shown in Fig. 6A, Ang-1 was weakly expressed at base
line. After stimulation with TNF-, Ang-1 expression levels
increased from base line to 2 h and peaked at about 6–24 h.
ESE-1 expression was weakly expressed at base line, and was
markedly induced at 2 h, peaking at 6 h with some expression
persisting up to 24 and 48 h. Similar results were observed in
synovial fibroblasts after stimulation with IL-1 (Fig. 6B). The
temporal onset of ESE-1 expression in response to inflamma-
tory cytokines followed by increases in Ang-1 levels further
support a potential role for ESE-1 in the regulation of Ang-1
gene expression.
Inflammatory Cytokine Stimulation Induces Binding of ESE-1
to a High Affinity Binding Site within the Ang-1 Promoter—To
identify the specific protein binding to the ETS Ang-1 site, gel
mobility shift assays were performed using whole cell extracts
derived from human primary synovial fibroblasts stimulated
with TNF-. As shown in Fig. 7 (lanes 3–8), TNF- stimulation
is associated with an inducible change in binding pattern to the
ETS Ang-1-binding site starting at position 1565. To identify
the protein specifically binding to this site, EMSAs were per-
formed in the presence or absence of antiserum to ESE-1. As
shown in Fig. 7 (lanes 9–14), the ESE-1 antibody is able to
block binding of the protein to the high affinity ETS Ang-1 site.
Similar results were seen with IL-1 (data not shown). This
suggests that the induction of Ang-1 is mediated by inducible
binding of the ESE-1 protein to the Ang-1 promoter.
Microarray Analysis of Ang-1 Expression in ESE-1-trans-
fected Cells—To further evaluate the role of Ang-1 as a poten-
tial target of ESE-1, the MCF-7 breast cancer cell line was
transiently transfected with a mammalian CMV expression
plasmid encoding ESE-1 (PCI-ESE-1). Several cell lines were
screened for high transfection efficiency and for expression of
ESE-1. The MCF-7 cell line was chosen because the transfec-
tion efficiency is routinely over 50% and ESE-1 is only weakly
expressed in these cells prior to transfection. Microarray anal-
FIG. 3. Transactivation of the Ang-1
promoter by a panel of ETS factors.
Transactivation of the 3.2-kb Ang-1 lucif-
erase reporter construct C (3040/199)
(300 ng) by a panel of ETS transcription
factors (150 ng each) compared with the
empty mammalian expression plasmid
(PCI, 150 ng) in HEK293 cells. The
change in luciferase activity is expressed
as fold induction compared with PCI.
FIG. 4. Gel mobility shift assays for ESE-1 binding to putative
ETS sites in the Ang-1 promoter. In vitro translated ESE-1 protein
(lanes 2, 4, 6) or control extract (lanes 1, 3, 5) was used with end-labeled
oligonucleotide probes encoding putative ETS sites starting at posit-
ions 2578 (lanes 1 and 2), 2199 (lanes 3 and 4), and 1565 (lanes 5
and 6).
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ysis was performed with total RNA extracted from the tran-
siently transfected cells after 24 h. Following ESE-1 transfec-
tion, a 2.4-fold induction of Ang-1 mRNA expression was
observed (Fig. 8A). Semi-quantitative RT-PCR was also per-
formed to confirm the changes observed by microarray (Fig.
8B). These results demonstrate low levels of Ang-1 and ESE-1
in control-transfected cells, and a similar increase in Ang-1
expression in ESE-1-transfected cells. Western blot analysis of
ESE-1-transfected cells confirmed increased expression of the
ESE-1 protein in these cells compared with control cells trans-
fected with empty vector (Fig. 8C). The results of these exper-
iments further support a direct role for ESE-1 in the regulation
of Ang-1 gene expression.
AML-1 Is Constitutively Expressed in Human Synovial Fi-
broblasts and Interacts Synergistically with ESE-1 and CBF-
to Regulate the Ang-1 Gene—AML-1 (CBF-/CBFA2) is a mem-
ber of the runt transcription factor family that was recently
shown to be one of the main factors regulating constitutive
expression of Ang-1 in hematopoietic cells (25). Targeted dis-
ruption of AML-1 leads to a marked reduction in Ang-1 expres-
sion in hematopoietic cells, resulting in defective angiogenesis
that can be rescued by administration of Ang-1. Because syno-
vial fibroblasts constitutively express low levels of Ang-1, we
postulated that AML-1 could also regulate the expression of
Ang-1 in these cells. Evaluation of AML-1 expression by RT-
PCR demonstrated constitutively high levels of AML-1 in the
synovial fibroblasts that did not change in response to TNF-
(Fig. 9A). Similar results were observed with IL-1 stimulation
(data not shown). Another transcription factor, core binding
factor  (CBF-), enhances the DNA binding activity of AML-1
(26, 27). This factor was also constitutively expressed at base
line in the synovial fibroblasts (data not shown).
We were also interested in determining whether AML-1 is
capable of transactivating the Ang-1 promoter. Cotransfec-
tion experiments with the Ang-1 promoter luciferase con-
struct C and increasing amounts of AML-1 resulted in a
maximal 3-fold increase in the activity of the Ang-1 promoter
(Fig. 9B). AML-1 has also been shown to interact synergisti-
cally with other ETS family members, including ETS-1,
ETS-2, and PU.1, to promote the transactivation of several
FIG. 5. Mutational analysis of the Ang-1 promoter. Transactivation studies of wild type (filled bars) and mutant ETS binding site
1565/1562 (open bars) Ang-1 luciferase reporter construct C (3040/199) (300 ng each) in HEK293 cells with increasing doses of ESE-1 (A).
The change in luciferase activity is expressed as fold induction compared with PCI. Transactivation studies of wild type (filled bars) and mutant
ETS binding site 1565/1562 (open bars) Ang-1 luciferase reporter construct C (3040/199) (300 ng each) in NIH3T3 fibroblasts after
stimulation with TNF- (50 ng/ml) (B). The change in luciferase activity is expressed as fold induction compared with the promoter construct in
unstimulated cells (DMEM supplemented with 10% FCS). In vitro translated ESE-1 protein (lanes 2, 4, and 6) or control extract (lanes 1, 3, and
5) in the presence (lanes 5 and 6) or absence (lanes 1–4) of ESE-1 antibody was used with end-labeled oligonucleotide probes encoding either the
wild-type ETS binding site starting at position 1565 on the Ang-1 promoter (lanes 1, 2, 5, and 6) or the mutated ETS binding site starting at
position 1565 (lanes 3 and 4) (C).
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other genes (28–30). Therefore, we tested the ability of
AML-1 to cooperate with the ETS factor ESE-1 to transacti-
vate the Ang-1 promoter. Cotransfection of AML-1 and ESE-1
resulted in a marked synergistic transactivation of the Ang-1
promoter (Fig. 9C). Whereas cotransfection with AML-1 or
ESE-1 alone only led to a 2–3-fold increase in Ang-1 promoter
activity, cotransfection of both factors resulted in a synergis-
tic 11-fold increase in Ang-1 promoter activity.
AML-1 also associates with CBF- to enhance the DNA
binding activity of AML-1. Similar synergistic transactivation
of the Ang-1 promoter was observed in cotransfection experi-
ments using all three transcription factors, ESE-1, AML-1, and
CBF- (Fig. 9D). Little to no induction of the Ang-1 promoter
was seen with low doses (75–100 ng) of CBF- (data not
shown). These results are consistent with the fact that CBF-
does not bind DNA directly, but rather enhances the binding of
AML-1 (CBF-). Weaker induction of the Ang-1 promoter by
AML-1 alone was observed in Fig. 9D than in 9C (3.5-fold
versus 11-fold) because lower amounts of the AML-1 plasmid
DNA (75 versus 100 ng) were used in these transfection exper-
iments while maintaining the same total amounts of DNA. The
combination of ESE-1, AML-1, and CBF- resulted in a 9-fold
induction of the Ang-1 promoter (Fig. 9D). Site-directed mu-
tagenesis of the ETS binding site 1565 to 1562 in the Ang-1
promoter resulted in a marked reduction in the synergistic
transactivation by the combination of ESE-1, AML-1, and
CBF- compared with the wild-type construct (Fig. 9D), further
supporting the requirement of this high affinity ESE-1 binding
site in activation of the Ang-1 promoter. The results of these
transactivation studies demonstrate that the interactions be-
tween AML-1, CBF-, and ESE-1 are more than additive and
result in synergistic regulation of Ang-1 gene expression.
Evaluation of ESE-1 and Ang-1 in Patients with Rheumatoid
Arthritis—We have previously shown that Ang-1 is expressed
in the synovium of patients with rheumatoid arthritis (10), and
that ESE-1 is expressed in rheumatoid synovium (15). Because
our results support a role for ESE-1 in regulating Ang-1, we
were interested in determining whether ESE-1 and Ang-1 are
expressed in similar regions of the rheumatoid synovium. Their
expression was evaluated by immunohistochemistry in serial
sections of tissue samples obtained from patients with RA.
Representative examples of the immunohistochemistry are
shown in Fig. 10. Ang-1 and ESE-1 exhibit very similar stain-
ing patterns, with strong expression in the synovial lining layer
as well as in individual cells within the subsynovium and with
a complete absence of staining in the isotype-matched control
sample. These results further support a role for ESE-1 in the
regulation of Ang-1 gene expression and angiogenesis in the
setting of inflammation.
FIG. 6. Assessment of ESE-1 and Ang-1 mRNA expression after
inflammatory stimulation. Semi-quantitative RT-PCR of ESE-1 and
Ang-1 mRNA expression in primary human synovial fibroblasts stim-
ulated with TNF- (5 ng/ml) (A) or IL-1 (100 pg/ml) (B) and harvested
at different time points (0, 2, 6, 24, and 48 h) after stimulation. GAPDH
is used as an internal control.
FIG. 8. Analysis of Ang-1 expression in ESE-1-transfected cells.
Microarray analysis in MCF-7 cells transfected with control (PCI) ex-
pression plasmid versus ESE-1-transfected cells. Arrow points to loca-
tion of Ang-1 on microarray grid. Total counts and fold induction of
Ang-1 are shown below grid (A). Assessment of ESE-1 and Ang-1 mRNA
expression in PCI and PCI-ESE-1-transfected cells by semi-quantita-
tive RT-PCR. GAPDH is used as internal control (B). Western blot
analysis of ESE-1 in PCI and PCI-ESE-1-transfected cells (C).
FIG. 7. Gel mobility shift assays with Ang-1 promoter high
affinity ETS binding site. In vitro translated ESE-1 protein (lane 2),
control extract (lane 1), or whole cell extracts (10 g) (lanes 3–14) from
human primary synovial fibroblasts stimulated with TNF- (5 ng/ml)
and harvested at different time points (0 h, lanes 3 and 9; 2 h, lanes 4
and 10; 6 h, lanes 5 and 11; 18 h, lanes 6 and 12; 24 h, lanes 7 and 13;
48 h, lanes 8 and 14) after stimulation in the presence (lanes 9–14) or
absence (lanes 3–8) of ESE-1 antibody used with end-labeled oligonu-
cleotide probe encoding the high affinity ETS binding site on the Ang-1
promoter starting at position 1565.
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DISCUSSION
Angiogenesis is required for the growth and proliferation of
inflammatory tissue in a number of diseases. Angiogenic
growth factors such as VEGF, bFGF, and Ang-1 are critical
mediators of angiogenesis. These angiogenic growth factors act
upon endothelial cells, enhancing their proliferation and mi-
gration to sites of inflammation. The release of inflammatory
cytokines and hypoxia promotes the local expression of these
growth factors. Inflammatory cytokines such as IL-1 and
TNF- have been shown to induce the expression of both VEGF
and bFGF (31–33). The results of our studies as well as others
have recently shown that Ang-1 expression is also stimulated
by TNF- (10, 11). The primary goal of our study was to identify
the transcriptional mechanisms responsible for mediating the
induction of the Ang-1 gene in the setting of inflammation.
The regulation of other angiogenic growth factors in the
setting of inflammation is dependent on several transcription
factors. Members of the Rel/NF-B family represent prototype
transcription factors that mediate inflammatory responses. Ac-
tivation of these factors does not require protein synthesis, as
they are sequestered in the cytoplasm, where they are bound
noncovalently to the endogenous inhibitors, the I-B proteins.
Upon stimulation by inflammatory cytokines or endotoxin,
these inhibitors are phosphorylated and proteolytically de-
graded, allowing NF-B to be translocated to the nucleus,
where it binds to the regulatory regions of target genes as a
homo- or heterodimer (34, 35). The induction of both bFGF and
VEGF by TNF- has been shown to be mediated at least in part
by NF-B (31). The promoters of both of these angiogenic
growth factors contain binding sites for NF-B. In contrast, we
were unable to identify obvious binding sites for NF-B within
the proximal 3 kb of the Ang-1 promoter.
The absence of putative NF-B binding sites in the Ang-1
promoter led us to look for alternative regulatory mechanisms.
Several other transcription factors have been identified to play
a role in mediating inflammatory responses, including ETS,
Egr-1, C/EBP, STAT, and AP-1 (36, 37). Among these, only
binding sites for AP-1 and ETS family members were identified
within the Ang-1 promoter. The AP-1 family member c-Jun has
been shown to be a critical transcriptional regulator of VEGF
FIG. 9. Evaluation of AML-1 in primary human synovial fibroblasts and on transactivation of the Ang-1 promoter. Semi-quantitative
RT-PCR of AML-1 mRNA expression in primary human synovial fibroblasts stimulated with TNF- (5 ng/ml) at different time points (0, 2, 6, 24,
and 48 h) after stimulation. GAPDH is used as an internal control (A). Transactivation studies of wild type Ang-1 luciferase reporter construct C
(3040/199) (300 ng) with increasing doses of AML-1 (B) and with cotransfections of AML-1 and ESE-1 (100 ng of each transcription factor) (C)
in HEK293 cells. Transactivation studies of wild type Ang-1 luciferase reporter construct C (filled bars) or mutant ETS binding site 1565/1562
Ang-1 luciferase reporter construct C (open bars) (150 ng of each) with AML-1, CBF-, and ESE-1 (75 ng of each) in HEK293 cells (D). The change
in luciferase activity is expressed as fold induction compared with the empty vectors (PCI  pCMV5).
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gene expression during inflammation and cooperate with the
transcription factor HIF-1 to regulate the VEGF gene in the
setting of hypoxia (38, 39).
The ETS genes are a family of at least thirty members that
function as transcription factors (23). All ETS factors share a
highly conserved DNA binding domain of 80–90 amino acids,
known as the ETS domain. ETS factors play a central role in
regulating genes involved in development, cellular differentia-
tion, and proliferation. Several studies have demonstrated a
role for members of the ETS factor family in inflammation and
angiogenesis. For example, the TNF- gene is regulated by
ETS-1 (24). TNF- can also induce the expression of ETS-1 and
is up-regulated in animal models of vascular inflammation
(40). ETS-1 has also been shown to be enriched in angiogenic
blood vessels and can cooperate with another transcription
factor, HIF-1, to regulate the expression of the VEGF receptor
Flk-1 (41, 42). We have recently demonstrated a role for the
ETS factor ESE-1 as a transcriptional mediator of inflamma-
tion (14). ESE-1 is inducible in several cell types in response to
inflammatory cytokines and endotoxin. In the current study we
demonstrate that, among a panel of ETS factors tested, only
ESE-1 was able to transactivate the Ang-1 promoter, and was
co-expressed with Ang-1 in primary synovial fibroblasts after
stimulation with inflammatory cytokines. That Ang-1 is indeed
a target for ESE-1 was further validated in transcriptional
profiling studies. We demonstrate that the endogenous Ang-1
gene is induced after overexpression of ESE-1 by transient
transfection, strongly suggesting that the endogenous Ang-1
gene is regulated by ESE-1.
The transcription factor AML-1 (CBF-/CBFA2) is a critical
regulator of constitutive Ang-1 gene expression in hematopoietic
cells (25). AML-1 belongs to the runt transcription factor family,
members of which share a 128-amino acid domain known as the
runt domain that mediates DNA binding as well as dimerization
to CBF- (CBFB) (43, 44). CBF- has no direct DNA binding
capability, but enhances binding of AML-1 to DNA (45). AML-1
has been shown to be involved in the regulation of a wide variety
of genes in cells of hematopoietic origin, including several B- and
T cell-specific genes, cytokines, and their receptors, and several
enzymes including neutrophil elastase, granzyme B, and my-
eloperoxidase (46–48). Other members of the runt transcription
factor family are also expressed in several other cell types. For
example, AML-3 (CBFA1) is involved in the regulation of the
osteopontin gene in skeletal tissues. Overlapping expression of
osteopontin and AML-3 was observed in osteoblasts, chondro-
cytes, and periosteal fibroblasts (49). We observed constitutive
expression of AML-1 in synovial fibroblasts that remained un-
changed after stimulation with inflammatory cytokines. This is
the first example that we are aware of demonstrating AML-1
expression in nonhematopoietic cells. Because Ang-1 is a known
target of AML-1 under normal conditions in hematopoietic cells,
this would also support a role for AML-1 in the regulation of
Ang-1 in synovial cells (25). AML-1 forms a ternary complex
together with CBF- and ETS-1 to regulate the expression of the
osteopontin gene, and AML-1 and ETS-1 have been shown to
synergistically transactivate the osteopontin promoter (49). We
similarly observed a synergistic response in transactivation of
the Ang-1 promoter with the combination of ESE-1 and AML-1,
suggesting that AML-1 may also act to promote the induction of
the Ang-1 gene under inflammatory conditions through cooper-
ativity with ESE-1, even though AML-1 expression levels remain
unchanged.
Several studies have demonstrated that there is marked
neovascularization within the rheumatoid synovium (50, 51).
In addition to its role in supplying blood to the inflamed syno-
vium, the endothelial cells derived from these new blood ves-
sels actively participate in the inflammatory response by re-
cruiting lymphocytes and releasing cytokines and angiogenic
factors (4). We recently showed that ESE-1 is also highly ex-
pressed in the synovium of patients with RA (15). We and
others (10) have also shown that Ang-1 is expressed in synovial
tissues from patients with RA. Ang-1 and ESE-1 were detected
not only around developing blood vessels but also within the
synovial lining layer and other less vascular regions within the
subsynovium. The similar expression pattern of ESE-1 and
Ang-1 in patients with RA further supports a role for ESE-1 as
a transcriptional regulator of Ang-1 expression in the setting of
inflammation. In addition to its role in promoting vessel mat-
uration, Ang-1 may also act to promote the migration of endo-
thelial cells to sites of active inflammation.
In summary, the results of our studies demonstrate that
Ang-1 is one of several critical regulators of angiogenesis that
is up-regulated in the setting of inflammatory conditions such
as rheumatoid arthritis. In contrast to other angiogenic factors,
the induction of the Ang-1 gene does not appear to be directly
dependent upon NF-B, but instead is mediated in part by the
ETS factor ESE-1 acting cooperatively with the runt transcrip-
tion factors AML-1 and CBF-.
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